The Board of Directors of Ajanta Pharma is scheduled to meet to consider an equity dividend. The meeting is set to take place on November 3, 2025, where the board will also review the unaudited financial results for the second quarter (Q2: Jul-Sep) and half year, ending September 30, 2025. In addition, the board will deliberate on a declaration of the 1st interim dividend for the financial year ending March 31, 2026.
Board Meeting for Dividend Consideration
Ajanta Pharma has announced that a meeting of its Board of Directors is scheduled for November 3, 2025. The primary agenda is to consider a proposal for an equity dividend. This decision reflects the company’s ongoing commitment to rewarding its shareholders and sharing the benefits of its financial performance.
Financial Results and Dividend Declaration
During the meeting, the Board will also review and approve the unaudited financial results for the second quarter (Q2: Jul-Sep) and half year which ended on September 30, 2025. In addition to these financial results, the board will also deliberate on the declaration of the 1st interim dividend for the financial year ending March 31, 2026.
Record Date for Interim Dividend
The company has also fixed November 10, 2025, as the record date for determining shareholders’ eligibility for the payment of the interim dividend, if declared. This step ensures the smooth and transparent distribution of benefits to the company’s investors.
Source: BSE
